Melanie Saville | Chief Scientific Officer
PATH
Melanie Saville, MBBS, is PATH’s Chief Scientific Officer. She leads PATH’s product development division, which includes a global team dedicated to the development, introduction, and scale of vaccines, medical devices, and diagnostics. Dr. Saville is a Fellow of the Academy of Medical Sciences (FMedSci) and chairs the World Health Organization’s Product Development for Vaccines Advisory Committee (WHO PDVAC). A physician specializing in virology, she has spent more than two decades developing and licensing vaccines that have reached billions of people worldwide. Before joining PATH, Dr. Saville served as Executive Director of Vaccine Research and Development at the Coalition for Epidemic Preparedness Innovations (CEPI), where she built a $1.5 billion portfolio that contributed to seven authorized COVID-19 vaccines, including Oxford/AstraZeneca and Moderna. As R&D and manufacturing lead for COVAX, she contributed to the delivery of 1.9 billion vaccine doses globally, with low- and middle-income countries receiving supplies within weeks of high-income nations. She is a principal architect of the 100 Days Mission, the G7/G20-endorsed framework for developing pandemic vaccines within 100 days of a declared threat. Her earlier work at Sanofi Pasteur contributed to the world’s first licensed dengue vaccine. Dr. Saville holds a medical degree, a master’s degree in medical virology, and a Bachelor of Science in molecular biology from University College London.
Appearances:
Day 1 (20th October) @ 10:15
One Shot, Many Frontiers: Combination Vaccines for a Healthier Lifetime
- How can combination vaccines support life-course immunisation strategies and close immunity gaps at every age?
- Could combining priority pathogens in a single shot improve vaccine coverage, or will it introduce new barriers for uptake and delivery?
- What is the economic value of combination vaccines?
- What standards do we need to ensure multi-antigen vaccines perform consistently without compromising safety or effectiveness?
- What strategies can we use to ensure broad accessibility of combination vaccines, including considerations around technology, adjuvants, and formulation?
- Which pairings have the strongest potential to reduce global disease burden, especially in regions with limited resources?
Day 2 (21st October) @ 12:00
Working Group: The way forward: how do we ensure that the priority combination vaccines are developed, licensed and used?
The session will present the results of a recent WHO-PATH effort to develop a systematic framework for prioritizing pediatric combination vaccines, and the priority vaccines that have emerged. Through an interactive panel discussion with active audience participation, the session will explore practical pathways for translating these priorities into vaccines that are developed, licensed, introduced and used at scale.
Day 2 (21st October) @ 12:45
Panel: From Bottleneck to Breakthrough: Reengineering Vaccine Clinical Development
The COVID-19 pandemic demonstrated that vaccine development can be dramatically accelerated, raising industry expectations for faster development timelines. Several years later, timelines have largely reverted to pre-COVID norms. At the same time, the vaccine landscape has become increasingly crowded and competitive.
In this environment, trial productivity has become a strategic differentiator. This panel will take stock of today’s vaccine development landscape and explore what developers can do differently to accelerate development. The discussion will focus on the levers with the greatest potential to improve speed and productivity, including the opportunities emerging in the age of AI, and bring together perspectives from biotech, large vaccine companies, and the public sector.
Stay up-to-date
Join our mailing list to receive exclusive content and offers.
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events